Winstgevend schreef op 2 januari 2018 23:21:
Pharming Group clinical trial status: Contrast-induced Nephropathy
Phase : 2
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple
(Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Recombinant Human C1 Esterase Inhibitor (Conestat Alfa)
in the Prevention of Contrast-induced Nephropathy in High-risk Subjects
(PROTECT): a Randomized, Placebo-controlled, Double-blind Single-center Trial
Study Start Date: January 2017
Estimated Primary Completion Date: February 2018
Estimated Study Completion Date: May 2018